Picture loading failed.

Anti-MET therapeutic antibody (Pre-made Emibetuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Emibetuzumab (INN) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer. It is in phase II trials for patients with NSCLC

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-178-1mg 1mg 3090
GMP-Bios-ab-178-10mg 10mg 21890
GMP-Bios-ab-178-100mg 100mg 148000
GMP-Bios-ab-178-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-MET therapeutic antibody (Pre-made Emibetuzumab biosimilar,Whole mAb)
INN Name Emibetuzumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesEli Lilly
Conditions Approvedna
Conditions ActiveGastric cancer;Non-small cell lung cancer;Cancer
Conditions Discontinuedna
Development Techna